Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels

What Was Tested

This randomized controlled trial paper looks at Glucagon.

There are no studies clearly defining the relationship between insulin levels, subcutaneous glucagon, and blood glucose.

Who Took Part

According to the abstract, 11 subjects were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the subjects took both Glucagon and the comparison in turn, acting as their own control.

Infused 6,6-dideuterated glucose was measured every 10 min, and EGP was determined using a validated glucoregulatory model.

Area under the curve (AUC) for glucose production was the primary outcome, estimated over 60 min.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 1, Glucagon, Glucose, Glucose Clamp Technique, Hypoglycemia and Insulin.

What This Means in Plain Language

The paper is a randomized and crossover study of Glucagon in 11 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Diabetes care), a journal based in United States.

More context: the Glucagon compound page, all human trials.